Skip to main content

Table 5 Perceptions of benefits, drawbacks, and limitations of prodromal AD/MCI due to AD in clinical practice

From: Use of mild cognitive impairment and prodromal AD/MCI due to AD in clinical care: a European survey

 

Strongly agree

Somewhat agree

Neither agree or disagree

Somewhat disagree

Strongly disagree

Benefits

 - Labeling the problem is helpful for patients and family members

53 (52)

33 (32)

6 (6)

4 (4)

6 (6)

 - A diagnosis is useful so the patient can be more involved in planning for the future

45 (44)

38 (37)

10 (10)

6 (6)

3 (3)

 - A diagnosis can be useful in motivating the patient to engage in risk reduction activities

43 (42)

40 (39)

10 (10)

5 (5)

4 (4)

 - A diagnosis helps the family with insurance planning

28 (27)

35 (34)

27 (26)

6 (6)

6 (6)

 - A diagnosis helps the family with financial planning

30 (29)

47 (46)

16 (16)

4 (4)

5 (5)

 - A diagnosis can be useful for including patients in clinical trials

71 (70)

23 (23)

5 (5)

3 (3)

0

 - Certain medications can be useful for treating some patients

26 (25)

39 (38)

13 (13)

10 (10)

14 (14)

 - A diagnosis is useful for the physician to plan the follow-up

58 (57)

29 (28)

7 (7)

5 (5)

3 (3)

Drawbacks and limitations

 - Diagnosing causes unnecessary worry for patients and family members

4 (4)

14 (14)

14 (14)

36 (35)

34 (33)

 - There is no approved treatment so it does not make sense to diagnose

13 (13)

3 (3)

12 (12)

23 (23)

51 (50)

 - It is too difficult to diagnose accurately or reliably

4 (4)

21 (21)

7 (7)

30 (30)

40 (39)

 - A diagnosis has no added value over the diagnosis of MCI

8 (8)

9 (9)

14 (14)

21 (21)

50 (49)

  1. All data are N (%)
  2. Abbreviation: MCI mild cognitive impairment